28
Participants
Start Date
January 10, 2021
Primary Completion Date
March 12, 2021
Study Completion Date
March 12, 2021
GLS4
It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.
RTV
"1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human."
TAF
It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
The First Hospital of Jilin University, Changchun
Sunshine Lake Pharma Co., Ltd.
INDUSTRY